A Phase 1/1b Open-Label Multicenter Repeat-Dose Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers
Bert O'Neil, MD
Primary Investigator
Jessica MacLean
Primary Investigator
Overview
This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of CPI-444 as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors.
Description
This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of CPI-444 as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Non-Small Cell Lung Cancer,Malignant Melanoma,Renal Cell Cancer,Head and Neck Cancer,Colorectal Cancer,Bladder Cancer
-
Age: Between 18 Years - 100 Years
-
Gender: All
